CD151 as a Prognostic Marker in Endometrial Cancer
Author Information
Author(s): Voss M A, Gordon N, Maloney S, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Berditchevski F, Sundar S
Primary Institution: Pan Birmingham gynaecological cancer centre, City Hospital, School of Cancer Sciences, University of Birmingham, Birmingham, UK
Hypothesis
The prognostic significance of tetraspanin CD151 expression in poor outcome endometrial cancers was evaluated.
Conclusion
CD151 is a novel marker in type 2 cancers that can guide therapeutic decisions.
Supporting Evidence
- CD151 expression was significantly higher in uterine papillary serous and clear cell carcinoma than in grade 3 endometrioid carcinoma.
- In univariate analysis, age, stage, histology type and CD151 were significant for both recurrence free and disease specific survival.
- CD151 was significant for RFS and DSS in triple negative tumours.
Takeaway
This study found that a protein called CD151 can help doctors understand how serious a type of cancer called endometrial cancer is, which can help them decide on treatment.
Methodology
Tissue microarray constructed from 156 poor outcome endometrial cancers, tested with immunohistochemistry and correlated with clinicopathological data.
Limitations
The study is limited to a specific cohort of endometrial cancers and may not be generalizable to all cancer types.
Participant Demographics
Patients with International Federation of Gynaecology and Obstetrics (FIGO) stage IA–IV uterine cancers.
Statistical Information
P-Value
P=0.036 and 0.033 for RFS and DSS respectively in triple negative tumours.
Confidence Interval
CI 2.55–7.49 for stage, 95% CI 1.060–3.109 for CD151.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website